Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Studyopen access
- Authors
- Shin, Seong Hoon; Lee, Ho Sup; Kim, Yang Soo; Choi, Young Jin; Kim, Sung Hyun; Kwon, Hyuk Chan; Oh, Sung Yong; Kang, Jung Hun; Sohn, Chang Hak; Lee, Sang Min; Baek, Jin Ho; Min, Young Joo; Kim, Choongrak; Chung, Joo Seop
- Issue Date
- Oct-2014
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Cancer pain; Sleep disturbance; Hydromorphone-OROS (HM-OROS)
- Citation
- CANCER RESEARCH AND TREATMENT, v.46, no.4, pp.331 - 338
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 46
- Number
- 4
- Start Page
- 331
- End Page
- 338
- URI
- https://scholarworks.bwise.kr/gnu/handle/sw.gnu/18728
- DOI
- 10.4143/crt.2013.130
- ISSN
- 1598-2998
- Abstract
- Purpose To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbance and relieving cancer pain. Materials and Methods One hundred twenty cancer patients with pain (numeric rating scale [NRS] >= 4) and sleep disturbance (NRS >= 4) were evaluated. The initial HM-OROS dosing was based on previous opioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug was permitted at the investigator's discretion. Pain intensity, number of breakthrough pain episodes, and quality of sleep were evaluated. Results A total of 120 patients received at least one dose of HM-OROS; 74 of them completed the final assessment. Compared to the previous opioids, HM-OROS reduced the average pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they preferred HM-OROS to the previous medication. The adverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea. Conclusion HM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. The AEs were manageable.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.